Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Weighted Average and Diluted) (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.4 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 37.93% year-over-year to -$0.4; the TTM value through Dec 2025 reached $0.2, up 112.5%, while the annual FY2025 figure was $0.2, 112.5% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.4 in Q4 2025 per APLS's latest filing, down from $1.67 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.67 in Q3 2025 and bottomed at -$2742.0 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$145.15, with a median of -$1.02 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 195.27% in 2021, then soared 455.32% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.53 in 2021, then rose by 1.96% to -$1.5 in 2022, then skyrocketed by 52.0% to -$0.72 in 2023, then surged by 59.72% to -$0.29 in 2024, then plummeted by 37.93% to -$0.4 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.4 in Q4 2025, $1.67 in Q3 2025, and -$0.33 in Q2 2025.